Search results
Results From The WOW.Com Content Network
CDC recommends meningococcal vaccination for all adolescents. CDC also recommends meningococcal vaccination for children and adults at increased risk for meningococcal disease. Follow the recommended immunization schedule to ensure that your patients get the meningococcal vaccines that they need.
Meningococcal vaccines also vary by the number of serogroups they provide protection against. Three conjugate vaccines are quadrivalent (4 serogroups: A, C, W, and Y). Two recombinant protein vaccines are monovalent (1 serogroup: B).
There are 3 types of meningococcal vaccines used in the United States: Meningococcal conjugate or MenACWY vaccines. Serogroup B meningococcal or MenB vaccines. Pentavalent or MenABCWY vaccine
The meningococcal conjugate vaccine or MCV4 was approved in 2005. It uses antigens taken from the polysaccharide capsule and then bound to a separate protein that targets the body's immune cells.
Menactra and Menveo. The first meningococcal conjugate vaccine (MCV-4), Menactra, was licensed in the US in 2005, by Sanofi Pasteur; Menveo was licensed in 2010, by Novartis. Both MCV-4 vaccines are approved by the Food and Drug Administration (FDA) for people 2 through 55 years of age.
Meningococcal vaccine is an active immunizing agent used to prevent infection caused by certain groups (A, B, C, W, and Y) of meningococcal bacteria (Neisseria meningitides). The vaccine works by causing your body to produce its own protection (antibodies) against the disease.
Meningococcal conjugate vaccine is used to prevent infection caused by serogroups A, C, W, and Y. This vaccine helps your body develop immunity to meningitis, but will not treat an active infection you already have. The Menactra brand of this vaccine is for use in children and adults between the ages of 9 months and 55 years old.
MenACWY conjugate vaccines are recommended for adults who have conditions that increase risk of meningococcal infection (see CDC: Adult Immunization Schedule by Age), such as. Anatomic or functional asplenia (including sickle cell disease) HIV infection. Persistent complement component deficiencies.
MenACWY vaccines (Menveo® and MenQuadfi®) help protect against 4 serogroups of the bacteria that cause meningococcal disease: A, C, W, and Y. This type of vaccine is also known as a serogroup A, C, W, and Y, or quadrivalent, meningococcal vaccine.
The meningococcal conjugate vaccine (MenACWY) protects against four types of meningococcal bacteria (types A, C, W, and Y). It is recommended for all kids and teens age 11 and older. Some types of MenACWY are given to younger children (as early as 8 weeks of age) if they have a higher risk of getting meningococcal disease.